DK1748791T3 - Neisseria Meningitidis IgtB LOS som hjælpestof - Google Patents

Neisseria Meningitidis IgtB LOS som hjælpestof

Info

Publication number
DK1748791T3
DK1748791T3 DK05745670.9T DK05745670T DK1748791T3 DK 1748791 T3 DK1748791 T3 DK 1748791T3 DK 05745670 T DK05745670 T DK 05745670T DK 1748791 T3 DK1748791 T3 DK 1748791T3
Authority
DK
Denmark
Prior art keywords
los
adjuvant
igtb
neisseria meningitidis
tri
Prior art date
Application number
DK05745670.9T
Other languages
English (en)
Inventor
Liana Juliana Josephine Steeghs
De Winkel Johannes Gerardus Joseph Van
Der Ley Peter Andre Van
Original Assignee
Staat Der Nederlanden Vert Doo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Staat Der Nederlanden Vert Doo filed Critical Staat Der Nederlanden Vert Doo
Application granted granted Critical
Publication of DK1748791T3 publication Critical patent/DK1748791T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Amplifiers (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Soft Magnetic Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Fats And Perfumes (AREA)
DK05745670.9T 2004-05-11 2005-05-11 Neisseria Meningitidis IgtB LOS som hjælpestof DK1748791T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04076401 2004-05-11
PCT/NL2005/000358 WO2005107798A1 (en) 2004-05-11 2005-05-11 NEISSERIA MENINGITIDIS IgtB LOS AS ADJUVANT

Publications (1)

Publication Number Publication Date
DK1748791T3 true DK1748791T3 (da) 2010-06-28

Family

ID=34928212

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05745670.9T DK1748791T3 (da) 2004-05-11 2005-05-11 Neisseria Meningitidis IgtB LOS som hjælpestof

Country Status (18)

Country Link
US (1) US20080138359A1 (da)
EP (1) EP1748791B1 (da)
JP (1) JP5174457B2 (da)
KR (1) KR101270838B1 (da)
CN (1) CN1997392B (da)
AT (1) ATE464066T1 (da)
AU (1) AU2005239963B2 (da)
BR (1) BRPI0511026C1 (da)
CA (1) CA2566409C (da)
DE (1) DE602005020608D1 (da)
DK (1) DK1748791T3 (da)
ES (1) ES2344114T3 (da)
MX (1) MXPA06013093A (da)
NZ (1) NZ551250A (da)
PL (1) PL1748791T3 (da)
PT (1) PT1748791E (da)
SI (1) SI1748791T1 (da)
WO (1) WO2005107798A1 (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904581D0 (sv) * 1999-12-15 1999-12-15 A & Science Invest Ab A novel helicobacter pylori-binding substance and use thereof
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
CA2808919C (en) 2005-12-22 2016-04-19 Glaxosmithkline Biologicals S.A. Streptococcus pneumoniae capsular saccharide vaccine
EP2476434A1 (en) 2006-03-30 2012-07-18 GlaxoSmithKline Biologicals S.A. Immunogenic composition
EP2687228B1 (en) 2007-06-26 2017-07-19 GlaxoSmithKline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
WO2009049013A2 (en) * 2007-10-09 2009-04-16 Tufts University Cholera vaccines
BRPI0913268A2 (pt) * 2008-05-30 2016-03-15 U S A As Represented By The Secretary Of The Army On Behalf Of Walter Reed Army vacina de vesícula de membrana externa nativa multivalente meningocócica, métodos de fabricação e uso da mesma
AU2010247255A1 (en) * 2009-05-14 2012-01-12 Sanofi Pasteur Meningococcal vaccine based on lipooligosaccharide (LOS) and Neisseria meningitidis protein
NZ597007A (en) 2009-05-14 2013-09-27 Sanofi Pasteur Meningococcus vaccine containing lipooligosaccharide (los) from modified strains of l6 immunotype neisseria meningitidis
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB201003920D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Method of treatment
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
AU2011231574A1 (en) 2010-03-26 2012-10-11 Glaxosmithkline Biologicals S.A. HIV vaccine
CA2812893A1 (en) 2010-09-27 2012-04-05 Glaxosmithkline Biologicals S.A. Vaccine
KR20120068647A (ko) * 2010-12-18 2012-06-27 아이진 주식회사 개선된 면역반응을 유도하는 백신
LT2729167T (lt) 2011-07-07 2018-06-25 De Staat Der Nederlanden, Vert. Door De Minister Van Vws Gram-neigiamų bakterijų detergento neturinčių išorinės membranos vezikulių gamybos būdas
GB201310008D0 (en) 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
EP3229833A1 (en) 2014-12-10 2017-10-18 GlaxoSmithKline Biologicals SA Method of treatment
KR102002034B1 (ko) 2015-07-09 2019-07-22 에스에프씨주식회사 고효율과 장수명을 갖는 유기 발광 소자
EP3263695A1 (en) 2016-06-29 2018-01-03 GlaxoSmithKline Biologicals SA Immunogenic compositions
US10918709B2 (en) * 2016-10-31 2021-02-16 Eyegene Inc. Immune modulator and vaccine composition containing the same
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9101359A (nl) 1991-08-07 1993-03-01 Nederlanden Staat Nieuw saccharide-peptide-conjugaat, werkwijze ter bereiding ervan alsmede een vaccin dat een dergelijk saccharide-peptide-conjugaat omvat.
CA2348928C (en) * 1998-11-03 2010-01-26 De Staat Der Nederlanden, Vertegenwoordigd Door De Minister Van Welzijn,Volksgezondheid En Cultuur Lps with reduced toxicity from genetically modified gram negative bacteria
GB0103170D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
EP1423142A1 (en) * 2001-08-31 2004-06-02 Chiron SRL. Helicobacter pylori vaccination with a combination of caga, vaca and nap proteins
KR101239242B1 (ko) * 2002-08-02 2013-03-11 글락소스미스클라인 바이오로지칼즈 에스.에이. 항원 조합물을 포함하는 나이세리아 백신 조성물
JP5275983B2 (ja) * 2006-06-12 2013-08-28 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン

Also Published As

Publication number Publication date
KR20070029742A (ko) 2007-03-14
WO2005107798A1 (en) 2005-11-17
CN1997392B (zh) 2011-06-01
AU2005239963B2 (en) 2011-01-06
ES2344114T3 (es) 2010-08-18
EP1748791A1 (en) 2007-02-07
EP1748791B1 (en) 2010-04-14
JP2007537248A (ja) 2007-12-20
DE602005020608D1 (de) 2010-05-27
PT1748791E (pt) 2010-07-15
US20080138359A1 (en) 2008-06-12
KR101270838B1 (ko) 2013-07-04
BRPI0511026C1 (pt) 2021-05-25
CA2566409C (en) 2012-12-04
JP5174457B2 (ja) 2013-04-03
ATE464066T1 (de) 2010-04-15
BRPI0511026B1 (pt) 2019-01-08
NZ551250A (en) 2010-03-26
AU2005239963A1 (en) 2005-11-17
SI1748791T1 (sl) 2010-07-30
PL1748791T3 (pl) 2010-08-31
MXPA06013093A (es) 2007-08-08
CN1997392A (zh) 2007-07-11
BRPI0511026A (pt) 2007-11-27
BRPI0511026B8 (pt) 2020-01-21
CA2566409A1 (en) 2005-11-17

Similar Documents

Publication Publication Date Title
DK1748791T3 (da) Neisseria Meningitidis IgtB LOS som hjælpestof
BRPI0409133A (pt) formulações farmacêuticas contendo metilnaltrexona
WO2006012209A3 (en) A new adjuvant composition
MX2011012836A (es) Adyuvantes sinteticos de glucopiranosil-lipido.
DK1187629T3 (da) Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
MX2010012999A (es) Vacuna de vesícula de membrana externa nativa multivalente del meningococo, método para su fabricación y uso.
DK1599478T3 (da) Dihydropteridinoner, fremgangsmåde til fremstilling af disse og anvendelse af disse som lægemiddel
NO20074908L (no) Preparater inneholdende fettsyrer og/eller derivater derav og et lavtemperatur-stabiliseringsmiddel
NO20031646L (no) Adjuvanssammensetning omfattende et immunostimulatorisk oligonukleotid og en tokol
PT1154790E (pt) Reforco da actividade bactericida de antigenios contra a neisseria com oligonucleotidos contendo motivos cg
CY1109582T1 (el) Συνδυασμενα μηνιγγοκοκκινα συζευγματα με κοινη πρωτεϊνη φορεα
EP2433647A3 (en) GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
BRPI0619795B8 (pt) composição imunogênica, composição adjuvante, e, uso de uma composição imunogênica e um adjuvante
WO2005097211A3 (en) Compositions as adjuvants to improve immune responses to vaccines and methods of use
EA200701128A1 (ru) Рекомбинантные штаммы bcg, обладающие повышенной способностью к высвобождению из эндосомы
NO20072253L (no) Forbedrede vaksiner
TW200626132A (en) Topical nepafenac formulations
BR0305767A (pt) Métodos e composições para a preparação de derivados de ácido 4-substituìdo 3-hidroxibutìrico
DK1506185T3 (da) Forbindelser og deres anvendelse som 5-HT-inhibitorer
DE60303961D1 (de) Modifizierte saccharide, deren konjugate sowie deren herstellung
AR049681A1 (es) Macrolidos preparados a partir de actinomicetos. composiciones farmaceuticas
WO2010070453A8 (en) Meningococcal vaccines including hemoglobin receptor
EP3381445A3 (en) Aqueous formulation of antibody stablised by antioxidants for parenteral administration
CY1112654T1 (el) Διαμορφομερη βακτηριακων προσκολλητινων
NO20081809L (no) Glukuronatsalt av en piperazinforbindelse